Pharmacologic control of CAR-T cell function using dasatinib
Evan W. Weber(Cancer Institute (WIA)), Rachel C. Lynn(Cancer Institute (WIA)), Elena Sotillo(Cancer Institute (WIA)), John Lattin(Cancer Institute (WIA)), Peng Xu(Cancer Institute (WIA)), Crystal L. Mackall(Cancer Institute (WIA))
Cited by 229Open Access
Abstract
Key Points Dasatinib potently and reversibly suppresses CAR-T cell cytotoxicity, cytokine secretion, and proliferation. Dasatinib could be repurposed as a safety switch to mitigate CAR-mediated toxicity in patients.
Related Papers
No related papers found
Powered by citation graph analysis